Heart Test Laboratories Inc (HSCS) Stock Price, Quote & News

Company Profile

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventi...

Industry: Medical Devices

Sector: Healthcare

Phone: 682 237 7781

Website: heartsciences.com

Address:

550 Reserve Street, Suite 360, Southlake, United States

Moneyybaggs Dec. 25 at 12:57 PM

$HSCS How long is the review process once the 510(K) application has been submitted to the FDA? When HSCS released commercial version 1.1 of MyoVista Insisights Simpson stated that they were making MEANINGFUL PROGRESS WITH EARLY ADOPTERS and ARE ENGAGED IN COMMERCIAL DISCUSSIONS WITH SEVERAL LEADING HEALTHCARE INSTITUTIONS and is LOOKING FORWARD TO ANNOUNCING KEY CUSTOMER DEVELOPMENTS IN THE NEAR TERM. The market didn’t give two shits. I do not think he is over promising and under delivering any more. He stated the the feedback from the institutions testing the product was very positive. There are barely 3M shares outstanding. Any substantial contract announcement and this stock jumps $20-30 dollars in the blink of an eye. I 🙏🙏🙏🙏🙏 the shorts are piling in down here. PHENOMENALLY

0 · Reply

JuliVeytsman Dec. 24 at 7:43 PM

$HSCS

0 · Reply

Moneyybaggs Dec. 24 at 2:57 PM

$HSCS Somebody snarfed up those 23.3K shares on the ask at $2.64 in a NY nanosecond!!! She’s about to blow her top!!! WILDLY

1 · Reply

alwayswin2025 Dec. 23 at 4:06 PM

$ASTI $DGXX $GNS $HSCS you suck

0 · Reply

TA_Kongen Dec. 23 at 11:43 AM

$HSCS On watch due to 510

0 · Reply

JarvisFlow Dec. 22 at 10:38 AM

Ascendiant Capital has updated their rating for HeartSciences ( $HSCS ) to Buy with a price target of 9.2.

0 · Reply

d_risk Dec. 17 at 6:26 PM

$HSCS - Heart Test Laboratories, Inc. - 10Q - Updated Risk Factors HSCS warns that future stock sales and new equity awards, including under its incentive plan, could significantly dilute existing holders and pressure the share price. #Healthcare #MarketRisk #IncentivePlan #StockPricePressure #EquityDilution 🟢 Added 🟠 Removed https://d-risk.ai/HSCS/10-Q/2025-12-15

1 · Reply

JohnTrack Dec. 16 at 11:55 PM

$HSCS hanging around this chart!

0 · Reply

JerrieGauze Dec. 16 at 11:33 PM

$HSCS

0 · Reply

JerrieGauze Dec. 16 at 11:32 PM

$HSCS Indemnity clause aint the santity claus lol BK or maybe Tampa Hot Babe aka…should buy this pile of crap

1 · Reply

HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Dec 15, 2025, 8:30 AM EST - 10 days ago

HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device

Dec 11, 2025, 8:30 AM EST - 14 days ago

HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1

Sep 11, 2025, 4:15 PM EDT - 3 months ago

HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

Aug 15, 2025, 9:00 AM EDT - 4 months ago

HeartSciences Announces Conference Participation and Investor Webinar

Jul 24, 2025, 4:15 PM EDT - 5 months ago

HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

Jun 4, 2025, 9:00 AM EDT - 7 months ago

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Jun 3, 2025, 9:00 AM EDT - 7 months ago

Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value

May 29, 2025, 9:00 AM EDT - 7 months ago

HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

May 20, 2025, 9:00 AM EDT - 7 months ago

HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025

May 8, 2025, 9:00 AM EDT - 8 months ago

HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

May 7, 2025, 9:00 AM EDT - 8 months ago

HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

May 1, 2025, 9:00 AM EDT - 8 months ago

HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program

Mar 13, 2025, 4:15 PM EDT - 10 months ago

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results

Mar 10, 2025, 9:00 AM EDT - 10 months ago

HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications

Dec 16, 2024, 4:15 PM EST - 1 year ago

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

Nov 13, 2024, 9:00 AM EST - 1 year ago

HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

Oct 14, 2024, 4:15 PM EDT - 1 year ago

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 12, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

Sep 12, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

Jul 29, 2024, 4:05 PM EDT - 1 year ago

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Jul 26, 2024, 9:00 AM EDT - 1 year ago

Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

Jul 25, 2024, 8:30 AM EDT - 1 year ago

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

Jul 11, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

Jun 4, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Regains Compliance with Nasdaq Listing Requirements

May 20, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

Apr 24, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

Apr 2, 2024, 4:15 PM EDT - 1 year ago

HeartSciences to Present at the LD Micro Invitational XIV Conference

Mar 26, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Mar 14, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Mar 12, 2024, 9:00 AM EDT - 1 year ago

HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

Mar 6, 2024, 9:00 AM EST - 1 year ago

HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology

Feb 26, 2024, 9:00 AM EST - 1 year ago

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Feb 12, 2024, 9:00 AM EST - 2 years ago

HeartSciences Expands its Scientific Advisory Board

Feb 1, 2024, 9:00 AM EST - 2 years ago

HeartSciences Appoints New Scientific Advisory Board Member

Jan 18, 2024, 8:00 AM EST - 2 years ago

HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

Jan 3, 2024, 4:15 PM EST - 2 years ago

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

Dec 14, 2023, 4:15 PM EST - 2 years ago

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

Dec 5, 2023, 8:00 AM EST - 2 years ago

HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

Nov 13, 2023, 8:45 AM EST - 2 years ago

HeartSciences' MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

Nov 3, 2023, 8:28 AM EDT - 2 years ago

Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)

ARQT SINT

Sep 14, 2023, 4:15 PM EDT - 2 years ago

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

Sep 12, 2023, 4:15 PM EDT - 2 years ago

HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase

Sep 11, 2023, 4:15 PM EDT - 2 years ago

HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards

Sep 7, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India

Aug 31, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Signs Distribution Agreement with FJ Medical, Denmark

Aug 24, 2023, 9:00 AM EDT - 2 years ago

HeartSciences' MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation

Aug 17, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

Jul 27, 2023, 9:00 AM EDT - 2 years ago

MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark

Jul 19, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results

Moneyybaggs Dec. 25 at 12:57 PM

0 · Reply

JuliVeytsman Dec. 24 at 7:43 PM

$HSCS

0 · Reply

Moneyybaggs Dec. 24 at 2:57 PM

$HSCS Somebody snarfed up those 23.3K shares on the ask at $2.64 in a NY nanosecond!!! She’s about to blow her top!!! WILDLY

1 · Reply

alwayswin2025 Dec. 23 at 4:06 PM

$ASTI $DGXX $GNS $HSCS you suck

0 · Reply

TA_Kongen Dec. 23 at 11:43 AM

$HSCS On watch due to 510

0 · Reply

JarvisFlow Dec. 22 at 10:38 AM

Ascendiant Capital has updated their rating for HeartSciences ( $HSCS ) to Buy with a price target of 9.2.

0 · Reply

d_risk Dec. 17 at 6:26 PM

1 · Reply

JohnTrack Dec. 16 at 11:55 PM

$HSCS hanging around this chart!

0 · Reply

JerrieGauze Dec. 16 at 11:33 PM

$HSCS

0 · Reply

JerrieGauze Dec. 16 at 11:32 PM

$HSCS Indemnity clause aint the santity claus lol BK or maybe Tampa Hot Babe aka…should buy this pile of crap

1 · Reply

JerrieGauze Dec. 16 at 11:27 PM

$HSCS The towel has been thrown.

0 · Reply

JohnTrack Dec. 16 at 10:08 PM

$HSCS news flash!! https://www.rapidticker.com/news/hscs-sec-filing-67962e

0 · Reply

DrTampa Dec. 16 at 5:00 AM

$HSCS tutes been buying...so have I!

0 · Reply

LLYW Dec. 15 at 9:57 PM

$HSCS losing 2 mil a quarter w only 2 mil cash and zero revenue. Offering coming up or delist . One of the two

0 · Reply

LLYW Dec. 15 at 9:31 PM

$HSCS lol 2,000 in sales ?? Wild

0 · Reply

MHM7700 Dec. 15 at 9:27 PM

quick 9% win on $HSCS. my covers were 50% @ 2.90 and 50% @ 2.75. https://www.stocktwits.com/MHM7700/message/639243026

0 · Reply

stockanalysis_ Dec. 15 at 9:26 PM

After Hours Gainers: $CCHH $IVP $RILY $JLHL $HSCS Save this screener: https://stockanalysis.com/markets/afterhours/gainers/?ref=saveontrading

0 · Reply

MHM7700 Dec. 15 at 9:26 PM

$HSCS short @ 3.09 PT @ 2.90 SL @ 3.25

0 · Reply

dbr_island Dec. 15 at 9:25 PM

$HSCS there it goes… 🚨KITT🚨loading at these levels Here’s why👇

0 · Reply

DylanGFM Dec. 15 at 9:24 PM

$AMCI $HSCS

1 · Reply

JohnTrack Dec. 15 at 7:42 PM

$HSCS fda 510k submission https://www.rapidticker.com/news/hscs-heartsciences-announces-fda-510k-submission-4cdc58

0 · Reply

DrTampa Dec. 15 at 4:22 PM

$HSCS well well well...FDA submission has finally happened just days after commercialization for myovista insights was announced! 🎉🎉🎉

1 · Reply

Market Cap	2.27M
Revenue (ttm)	20,000.00
Net Income (ttm)	-6.61M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	11,938
Avg Vol	455,542
Day's Range	N/A - N/A
Shares Out	656,000.00
Stochastic %K	24%
Beta	3.16
Analysts	Strong Sell
Price Target	$13.50